Simulations Plus (NASDAQ:SLP) Issues Quarterly Earnings Results

Simulations Plus (NASDAQ:SLP) issued its earnings results on Thursday. The technology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.06, Zacks reports. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The company had revenue of $22.43 million during the quarter, compared to analysts’ expectations of $21.93 million. During the same period in the prior year, the business earned $0.20 EPS. The firm’s quarterly revenue was up 22.5% on a year-over-year basis. Simulations Plus updated its FY25 guidance to $1.07-1.20 EPS.

Simulations Plus Price Performance

Shares of NASDAQ SLP traded down $0.95 during mid-day trading on Thursday, hitting $23.82. The company had a trading volume of 351,146 shares, compared to its average volume of 175,219. The company has a market capitalization of $478.59 million, a PE ratio of 59.55 and a beta of 0.89. The business’s 50-day simple moving average is $30.38 and its 200 day simple moving average is $30.38. Simulations Plus has a 1-year low of $23.00 and a 1-year high of $51.22.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. William Blair reissued an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp increased their price objective on shares of Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.40.

Insider Buying and Selling

In other news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the sale, the director now directly owns 3,402,584 shares of the company’s stock, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 19.40% of the stock is currently owned by insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.